China's Jiangsu Hengrui in R&D effort with MD Anderson

Lab work

A 3-year oncology pact between Lianyungang-based Jiangsu Hengrui Medicine and the MD Anderson Cancer Center at the University of Texas in Houston will work with an immuno-oncology focus on combination therapies, personalized medicine and new treatment opportunities.

In a press release, the research effort was said to be aimed at bringing together "the scientific and clinical capabilities of MD Anderson and Jiangsu Hengrui Medicine."

The effort in Texas comes after the firm said last month it had entered a research pact with New York's Albert Einstein College of Medicine to study cancer therapies aimed at discovering new targets for development.


Survey: The Critical Role of Innovation in Launching Successful OTC Products

This research aims to understand the importance of product innovation and dose forms in driving new product design and development, consumer engagement and purchase interest for Over-the-Counter medicines. The first 50 qualified respondents will receive a $5 Amazon gift card. Take the survey now.

"The collaboration will also further strengthen Hengrui's leading position in oncology drug development in China, especially in the field of personalized medicine and immuno-oncology," said Guoqing Cao, VP of Jiangsu Hengrui Medicine.

Hengrui has a PD-1 drug candidate, SHR-1210, and last year out-licensed ex-China rights to Incyte as it moves further into drug discovery. Incyte ($INCY) paid $25 million upfront for a candidate that Hengrui has previously said it expects to enter a Phase II trial in patients with solid tumor cancers.

Also last year, the company announced plans to invest as much as $240 million to build a biopharmaceutical manufacturing plant in Jiangsu Province capable of making export-quality products, among a slew of deals made to build out a manufacturing and research effort in oncology and other therapeutic areas such as cardiovascular and metabolic diseases.

- here's the release

Suggested Articles

Neopharma, which has been buying and building plants for several years, is buying a sterile injectables plant and assets in Japan from India’s Lupin. 

In a warning letter, the FDA details how a Chinese OTC drugmaker handed over documents faked just for the agency's inspection—and admitted it.

WuXi Biologics expects to have a plant in Europe complete in 2021 as a capacity race plays out among Asia’s rapidly growing biologics CDMOs.